RhumbLine Advisers
IRD

RhumbLine Advisers’s Opus Genetics IRD Stock Holding History

RhumbLine Advisers’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26
Closed -$39 – 4350
2024
Q2 		$39 Sell
26
-3
-10% -$5 ﹤0.01% 4353
2024
Q1 		$58 Hold
29
– – ﹤0.01% 4235
2023
Q4 		$87 Hold
29
– – ﹤0.01% 4250
2023
Q3 		$97 Hold
29
– – ﹤0.01% 4282
2023
Q2 		$125 Buy
+29
New +$138 ﹤0.01% 4365

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's IRD Position: Q3 2024 in Review

RhumbLine Advisers sold out of Opus Genetics (IRD) in Q3 2024, closing a stake of 26 shares — an estimated $39 sold.

RhumbLine Advisers first reported a position in IRD in Q2 2023 and held it in 5 quarters. The position peaked at $125 in Q2 2023. 38 funds tracked by Wall St. Rank hold IRD as of Q3 2024.

  • RhumbLine Advisers reported no remaining Opus Genetics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 26 Opus Genetics shares in Q3 2024, an estimated $39.
  • RhumbLine Advisers first reported a position in Opus Genetics in Q2 2023 and held it in 5 quarters.
  • RhumbLine Advisers's Opus Genetics position peaked at $125 in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.